📊 KYNB Key Takeaways
Is Kyntra Bio, Inc.. (KYNB) a Good Investment?
Kyntra Bio exhibits severe financial distress with negative stockholders equity of -$30M, indicating technical insolvency. Despite reported net income of $183.5M, the company's core business is fundamentally broken: operating income is -$45.9M, operating cash flow is negative at -$4.8M, and revenue is flat at $6.4M. The positive net income appears attributable to one-time non-operating gains and masks an unsustainable operational model with heavy debt burden and no path to profitability.
Headline profitability is driven by non-operating/one-time items while core operations remain deeply unprofitable, evidenced by a large operating loss and negative free cash flow on flat revenue. Despite a solid near-term liquidity buffer, negative equity, high leverage, and weak interest coverage create elevated financial risk and potential dilution or refinancing pressure.
Why Buy Kyntra Bio, Inc.. Stock? KYNB Key Strengths
- Cash position of $47.9M provides near-term operational runway
- Current ratio of 3.39x indicates adequate short-term liquidity
- One-time net income event provided temporary capital relief
- Strong near-term liquidity (current ratio >3x, sizable cash)
- Low capital intensity (minimal capex)
- Some revenue base despite early stage
KYNB Stock Risks: Kyntra Bio, Inc.. Investment Risks
- Negative stockholders equity of -$30M indicates technical insolvency and negative book value per share
- Operating cash flow is negative (-$4.8M) signaling unsustainable core operations and cash burn
- Operating income deeply negative at -$45.9M with zero revenue growth in pharmaceutical sector demands ongoing investment
- Interest coverage ratio of -5.2x indicates inability to service $75M debt from operating earnings
- Liabilities exceed assets ($115.1M vs $119.6M assets) with deteriorating equity position unsustainable long-term
- Large and persistent operating losses
- Negative stockholders' equity indicates fragility
- High debt with poor interest coverage and refinancing risk
Key Metrics to Watch
- Operating cash flow trend - critical indicator of business viability
- Stockholders equity progression - watch for further deterioration toward insolvency
- Revenue growth trajectory - flat pharma revenues unsustainable without pipeline advancement
- Cash burn rate and runway - determines if $47.9M cash is sufficient
- Debt refinancing capability - ability to manage $75M obligation with negative equity
- Operating cash flow/burn rate
- Interest coverage and debt maturities
Kyntra Bio, Inc.. (KYNB) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 3.39x current ratio provides a solid financial cushion.
KYNB Profit Margin, ROE & Profitability Analysis
KYNB vs Healthcare Sector: How Kyntra Bio, Inc.. Compares
How Kyntra Bio, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Kyntra Bio, Inc.. Stock Overvalued? KYNB Valuation Analysis 2026
Based on fundamental analysis, Kyntra Bio, Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Kyntra Bio, Inc.. Balance Sheet: KYNB Debt, Cash & Liquidity
KYNB Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Kyntra Bio, Inc..'s revenue has declined by 88% over the 5-year period, indicating business contraction. The most recent EPS of $-11.89 indicates the company is currently unprofitable.
KYNB Revenue Growth, EPS Growth & YoY Performance
KYNB Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $123.0K | -$17.1M | $-4.25 |
| Q2 2025 | $998.0K | -$3.0M | $-0.73 |
| Q1 2025 | $2.7M | $4.6M | $0.05 |
| Q3 2024 | $40.1M | -$17.1M | $-0.17 |
| Q2 2024 | $44.3M | -$15.5M | $-0.16 |
| Q1 2024 | $36.2M | -$32.9M | $-0.33 |
| Q3 2023 | $15.7M | -$63.6M | $-0.65 |
| Q2 2023 | $29.8M | -$72.6M | $-0.78 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Kyntra Bio, Inc.. Dividends, Buybacks & Capital Allocation
KYNB SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Kyntra Bio, Inc.. (CIK: 0000921299)
📋 Recent SEC Filings
❓ Frequently Asked Questions about KYNB
What is the AI rating for KYNB?
Kyntra Bio, Inc.. (KYNB) has a Combined AI Rating of SELL from Claude (STRONG SELL) and ChatGPT (SELL) with 79% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are KYNB's key strengths?
Claude: Cash position of $47.9M provides near-term operational runway. Current ratio of 3.39x indicates adequate short-term liquidity. ChatGPT: Strong near-term liquidity (current ratio >3x, sizable cash). Low capital intensity (minimal capex).
What are the risks of investing in KYNB?
Claude: Negative stockholders equity of -$30M indicates technical insolvency and negative book value per share. Operating cash flow is negative (-$4.8M) signaling unsustainable core operations and cash burn. ChatGPT: Large and persistent operating losses. Negative stockholders' equity indicates fragility.
What is KYNB's revenue and growth?
Kyntra Bio, Inc.. reported revenue of $6.4M.
Does KYNB pay dividends?
Kyntra Bio, Inc.. does not currently pay dividends.
Where can I find KYNB SEC filings?
Official SEC filings for Kyntra Bio, Inc.. (CIK: 0000921299) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is KYNB's EPS?
Kyntra Bio, Inc.. has a diluted EPS of $45.37.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is KYNB a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Kyntra Bio, Inc.. has a SELL rating with 79% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is KYNB stock overvalued or undervalued?
Valuation metrics for KYNB: ROE of N/A (sector avg: 15%), net margin of 2,848.6% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy KYNB stock in 2026?
Our dual AI analysis gives Kyntra Bio, Inc.. a combined SELL rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is KYNB's free cash flow?
Kyntra Bio, Inc..'s operating cash flow is $-4.8M, with capital expenditures of $38.0K. FCF margin is -74.7%.
How does KYNB compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 2,848.6% (avg: 12%), ROE N/A (avg: 15%), current ratio 3.39 (avg: 2).